INSP241018C180000
- 15.62
- -16.39-51.20%
Inspire Medical Systems Newsroom
Baird Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Raises Target Price to $240
Mizuho Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Cuts Target Price to $230
RBC Capital Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
RBC Capital Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)
Jefferies Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $230
Truist Financial Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Announces Target Price $240
Leerink Partners Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Raises Target Price to $197
Inspire Medical Systems Is Maintained at Market Perform by Leerink Partners
Inspire Medical Systems Analyst Ratings
Lake Street Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $270
Lake Street Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
Morgan Stanley Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $210
Buy Rating for Inspire Medical Systems Amid Positive Trends and Promising New Product Launch
Maintaining Hold on Inspire Medical Systems Amid Solid Q2 Performance and Cautious H2 Revenue Outlook
Inspire Medical Systems Price Target Maintained With a $260.00/Share by RBC Capital
Inspire Medical Systems Analyst Ratings
Baird Maintains Outperform on Inspire Medical Systems, Lowers Price Target to $200
Inspire Medical Systems: Hold Rating Amidst Strong Financials and Emerging Market Uncertainties
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP), Definitive Healthcare Corp (DH) and Bicycle Therapeutics (BCYC)